Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?

Core Insights - Corcept Therapeutics reported third-quarter 2025 earnings of 16 cents per share, missing the Zacks Consensus Estimate of 18 cents, and down from 41 cents per share in the same quarter last year [2] - Revenues for the third quarter increased approximately 14% year over year to $207.6 million, but fell short of the Zacks Consensus Estimate of $219 million, with the revenue solely coming from product sales of the Cushing's syndrome drug, Korlym [2] Financial Performance - Revenues from Korlym missed the model estimate of $222.6 million [3] - Research and development expenses rose 16% year over year to $68.8 million, while selling, general and administrative expenses surged around 68.2% year over year to $124 million [3] - Operating expenses increased 30.8% year over year to $197.4 million in the third quarter [3] - Cash and investments as of September 30, 2025, totaled $524.2 million, up from $515 million as of June 30, 2025 [3] 2025 Guidance - Corcept lowered its total revenue guidance for 2025, now expecting total revenues in the range of $800-$850 million, down from the previous projection of $850-$900 million [4] Estimate Trends - Fresh estimates have trended downward over the past month, with the consensus estimate shifting down by 36.91% [5] VGM Scores - Corcept has a Growth Score of B but lags in Momentum Score with an F, and has an aggregate VGM Score of D, placing it in the bottom 40% for the investment strategy [6] Industry Comparison - Corcept is part of the Zacks Medical - Drugs industry, where United Therapeutics reported revenues of $799.5 million for the last quarter, reflecting a year-over-year change of +6.8% [8] - United Therapeutics is expected to post earnings of $6.74 per share for the current quarter, representing a year-over-year change of +8.9% [9]